Jobs

The UBC Michael Smith Laboratories at the University of British Columbia in Vancouver invites applications for a Research Associate (RA) position in Evolutionary Biochemistry to join the laboratory of Dr. Nobuhiko Tokuriki. The successful candidate will use microfluidic systems to perform single enzyme kinetics and high-throughput enzyme screening. The candidate will work on enzyme systems including alkaline phosphatase, phosphotriesterase, and APOBEC.

AdLab, a bioinformatics laboratory in the Research Center of the CHU de Québec – Université Laval is deeply involved in data integration, machine learning, deep learning, and the application of large language models to analyse biological big data. Its multidisciplinary team consists of bioinformaticians, data scientists, and biostatisticians working together to push the boundaries of computational biology.

The rapid advancements in ‘omics’ technologies—such as genomics, transcriptomics, proteomics, and metabolomics—are revolutionizing our understanding of biological mechanisms. These technologies, however, generate vast amounts of heterogeneous data that require sophisticated computational approaches. AdLab  is dedicated to developing cutting-edge tools and pipelines to efficiently process and integrate multi-omics data, particularly those obtained from next-generation sequencing platforms and including single-cell and proteomics data. To support this mission, we are seeking a skilled bioinformatician to join our team.

The University of Calgary’s Charbonneau Cancer Institute has a thriving research program focused on multi-omic profiling of cancer patients for precision medicine applications to cancer patients in Alberta and beyond. This program is integrated within the Marathon of Hope Cancer Centers Network, a pan-Canadian initiative aiming to close the gap between research and patient care. In this position, the recruited bioinformatician will (1) analyze multi-omic datasets to identify and study therapeutic targets for precision therapy in solid tumors, and (2) contribute to implementation of a clinical reporting system of molecular data results.

Position: Bioinformatician I
Location: MaRS Centre, Toronto
Department: Drug Discovery Program
Reports To: Scientific Advisor
Salary: Commensurate with level of experience; total compensation includes a competitive benefits plan (Sun Life), plus a defined benefit pension plan (HOOPP)
Hours: 35 hours/week
Job Type: Hybrid
Status: Full-Time, Temporary (1-year contract with possible conversion to permanent position)

The Ontario Institute for Cancer Research (OICR) is seeking a Bioinformatician who possesses the relevant training to join the Drug Discovery (DD) Program. The program aims to help efficiently translate discoveries made in Ontario’s labs into novel oncology therapies, spanning the entire drug discovery process from target identification and validation to clinical candidate selection.  The DD Program is collaborating with OICR’s Adaptive Oncology (AO) to develop computational tools to identify and prioritize biological targets and biomarkers. The AO Program seeks to develop knowledge and approaches to monitor cancer over time and in response to treatment, to enable precise and proactive clinical management.

This position is temporary, full-time for one-year, with the possibility of conversion to a permanent position.

The successful candidate will work closely with data scientists and biologists from OICR’s Adaptive Oncology and Drug Discovery programs to co-develop novel algorithms/methods and pipelines for target/biomarker discovery. This is an exciting opportunity to learn about the latest developments in drug discovery and the use of various bioinformatic and machine learning approaches in computational biology, while contributing to the development of new treatments for cancer.

While most work is completed remotely, there will be occasional onsite team meetings or events, where attendance is expected.

About OICR

OICR is Ontario’s cancer research institute. We bring together people from across the province and around the world to improve the lives of everyone affected by cancer. We take on the biggest challenges in cancer research and deliver real-world solutions to find cancer earlier and treat it more effectively. We are committed to helping people living with cancer, as well as future generations, live longer and healthier lives.

Launched in December 2005, OICR is an independent institute funded by the Government of Ontario through the Ministry of Colleges and Universities.

For more information about OICR, please visit the website at www.oicr.on.ca.

To learn more about working at OICR, visit our career page.

The Michael Smith Laboratories at the University of British Columbia in Vancouver, Canada, invites applications for a Research Associate position in Next-Generation RNA Therapeutics to join a dynamic and multidisciplinary team under the co-supervision of Dr. Anna Blakney and Dr. Jay Kizhakkedathu. The successful candidate will work on a project to develop new polymeric strategies for delivery of RNA. The Blakney Lab at UBC (blakneylab.msl.ubc.ca) develops next-generation RNA vaccines and therapies based on self-amplifying RNA and using interdisciplinary approaches including bioengineering, immunology, molecular biology and bioinformatics. The Kizhakkedathu lab (https://cbr.ubc.ca/our-people/investigators/jayachandran-kizhakkedathu/) develops novel polymers and biomaterials as therapeutics and devices.

Project: RNA medicines have gained considerable momentum in the past few years with the approval of Onpattro and the COVID-19 messenger RNA vaccines. While lipid nanoparticles (LNPs) are the state-of-the-art delivery system for RNA, we recently discovered that polymeric nanoparticles are less inflammatory and induce higher protein expression than LNPs. For this project, we are keen to explore the polymer design space for RNA delivery for a variety of applications. The PDF will work with the Blakney and Kizhakkedathu labs to design and synthesize novel polymers, and test them for RNA delivery and immunogenicity in vivo in preclinical models. We anticipate that polymers are a clinically translatable delivery system for RNA therapeutics.